Attitudes towards pharmaceutical companies in the UK
Welcome to ABPI-Ipsos Pharmaceutical Reputation Index. Read further to find out more about the reputation of pharmaceutical companies operating in the UK.
About this study
This study outlines some of the headlines and key insights from a year of research with the public, healthcare professionals and Members of Parliament to find out what they really think and feel about pharmaceutical companies in the UK. We’ve combined ongoing qualitative and quantitative research with in-depth analysis to bring you a comprehensive snapshot of the industry’s reputation. The research available on this website was conducted between July 2020 and March 2021, with plans for future research.
Whether you’re interested in stakeholder perceptions on topics such overall sector awareness through to granular issues around transparency, access to medicines, innovation and patient focus and more, you will find useful insights here.
Many assumptions are made about the reputation of the pharmaceutical industry. Here, we explore exactly what people know, think and feel about the sector – and why it matters. Shaped by a spectrum of memories, expectations and associations, we’ve seen preconceptions about the sector being challenged.
We’ll show you how the sector is seen from the outside – and the opportunities and challenges this brings.
*Based on data from the UK General Public
The events of the past year have challenged long-held beliefs and highlighted the technological and scientific expertise inherent in the sector. However, the UK public often have limited knowledge and understanding of the industry. Read more to find out what they think about the pharmaceutical companies operating in the UK and why.
Members of Parliament
Understanding the views of MPs is a critical to understanding the industry’s legislative barriers in the UK. Policy makers views have been challenged just as much as those of the public. Here, we’ll uncover the reputation of the sector in Westminster and how it’s changing.
Healthcare professionals (HCPs) are in many ways closer to the pharmaceutical industry than the other audiences in this study. Here, we explore what they think of the sector and how they rate their interactions with it.
The pandemic has shone a spotlight on pharma. It has raised the profile of individual companies and unprecedented advances in technology and collaboration between business and government has helped to change the course of the pandemic in the UK.
Our research has uncovered how the pandemic has had a transformative impact on how different groups view the sector.
Using data collected over the course of a year, we’ve analysed how the sector’s response to COVID has shaped public opinion. Drawing on both quantitative data and qualitative feedback, we explore the impact of COVID-19 on how the public think and feel about the sector.
Much like the public, parliamentarians have been impressed by the sector’s pandemic response. Read further to understand how COVID-19 has shaped opinion of the sector in Westminster.
How have healthcare professionals’ opinions of pharmaceutical companies changed as a result of the pandemic. We’ve asked a range of HCPs what they think about the sector’s response to the pandemic. Drawing on survey data and granular verbatim feedback, we’ve assessed the extent to which this is shaping their perceptions of the sector.
We used different research methodologies to provide a comprehensive snapshot of the industry’s reputation. Click on the link below to find more details.